FBIO241115C7500
- 0.05
- 0.000.00%
Fortress Biotech Newsroom
Roth MKM Maintains Fortress Biotech(FBIO.US) With Buy Rating, Raises Target Price to $13
Fortress Biotech Analyst Ratings
Fortress Biotech's Strategic Financial Moves and Clinical Pipeline Promise Bright Revenue Prospects: Pantginis Issues Buy Rating
Fortress Biotech Analyst Ratings
Fortress Biotech Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Fortress Biotech (FBIO), BioLife Solutions (BLFS)
Analysts Conflicted on These Healthcare Names: Fortress Biotech (FBIO), GoodRx Holdings (GDRX) and Adaptimmune Therapeutics (ADAP)
Buy Rating Affirmed: A Promising Outlook for Fortress Biotech Amid Upcoming Regulatory Milestones and Strategic Investments
Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target
Fortress Biotech Analyst Ratings
Alliance Global Partners Initiates Coverage On Fortress Biotech With Buy Rating, Announces Price Target of $5
Fortress Biotech Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Fortress Biotech (FBIO) and Phreesia (PHR)
Roth MKM Maintains Buy on Fortress Biotech, Lowers Price Target to $15
Fortress Biotech Analyst Ratings
B. Riley Trims Fortress Biotech's Price Target to $4 From $6, Keeps Buy Rating
Cantor Fitzgerald Reiterates Overweight on Fortress Biotech, Maintains $5 Price Target
Fortress Biotech Analyst Ratings
Cantor Fitzgerald Maintains Overweight on Fortress Biotech, Lowers Price Target to $5
Benchmark Reiterates Speculative Buy on Fortress Biotech, Maintains $5 Price Target